AAPL   317.39 (-0.91%)
FB   210.45 (-1.92%)
MSFT   179.46 (-2.69%)
GOOGL   1,497.87 (-1.26%)
AMZN   2,115.68 (-1.74%)
NVDA   298.44 (-3.32%)
BABA   213.55 (-2.06%)
MU   57.69 (-2.22%)
GE   12.32 (-1.68%)
TSLA   888.53 (-1.21%)
AMD   55.24 (-3.56%)
T   38.62 (+0.03%)
ACB   1.64 (-2.38%)
F   7.93 (-1.25%)
NFLX   383.72 (-0.59%)
PRI   134.54 (-1.36%)
BAC   34.42 (-1.26%)
DIS   139.20 (-0.83%)
GILD   67.47 (+0.70%)
AAPL   317.39 (-0.91%)
FB   210.45 (-1.92%)
MSFT   179.46 (-2.69%)
GOOGL   1,497.87 (-1.26%)
AMZN   2,115.68 (-1.74%)
NVDA   298.44 (-3.32%)
BABA   213.55 (-2.06%)
MU   57.69 (-2.22%)
GE   12.32 (-1.68%)
TSLA   888.53 (-1.21%)
AMD   55.24 (-3.56%)
T   38.62 (+0.03%)
ACB   1.64 (-2.38%)
F   7.93 (-1.25%)
NFLX   383.72 (-0.59%)
PRI   134.54 (-1.36%)
BAC   34.42 (-1.26%)
DIS   139.20 (-0.83%)
GILD   67.47 (+0.70%)
AAPL   317.39 (-0.91%)
FB   210.45 (-1.92%)
MSFT   179.46 (-2.69%)
GOOGL   1,497.87 (-1.26%)
AMZN   2,115.68 (-1.74%)
NVDA   298.44 (-3.32%)
BABA   213.55 (-2.06%)
MU   57.69 (-2.22%)
GE   12.32 (-1.68%)
TSLA   888.53 (-1.21%)
AMD   55.24 (-3.56%)
T   38.62 (+0.03%)
ACB   1.64 (-2.38%)
F   7.93 (-1.25%)
NFLX   383.72 (-0.59%)
PRI   134.54 (-1.36%)
BAC   34.42 (-1.26%)
DIS   139.20 (-0.83%)
GILD   67.47 (+0.70%)
AAPL   317.39 (-0.91%)
FB   210.45 (-1.92%)
MSFT   179.46 (-2.69%)
GOOGL   1,497.87 (-1.26%)
AMZN   2,115.68 (-1.74%)
NVDA   298.44 (-3.32%)
BABA   213.55 (-2.06%)
MU   57.69 (-2.22%)
GE   12.32 (-1.68%)
TSLA   888.53 (-1.21%)
AMD   55.24 (-3.56%)
T   38.62 (+0.03%)
ACB   1.64 (-2.38%)
F   7.93 (-1.25%)
NFLX   383.72 (-0.59%)
PRI   134.54 (-1.36%)
BAC   34.42 (-1.26%)
DIS   139.20 (-0.83%)
GILD   67.47 (+0.70%)
Log in

NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, Forecast & News

$266.71
+6.67 (+2.56 %)
(As of 02/21/2020 10:04 AM ET)
Today's Range
$267.53
Now: $266.71
$269.97
50-Day Range
$206.15
MA: $232.73
$266.68
52-Week Range
$94.75
Now: $266.71
$270.15
Volume3,358 shs
Average Volume145,665 shs
Market Capitalization$14.62 billion
P/E Ratio52.71
Dividend YieldN/A
Beta1.57
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLPG
CUSIPN/A
Phone321-534-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$375.54 million
Book Value$27.99 per share

Profitability

Net Income$-34,560,000.00

Miscellaneous

EmployeesN/A
Market Cap$14.62 billion
Next Earnings DateN/A
OptionableOptionable

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.


GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions

What is GALAPAGOS NV/S's stock symbol?

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

What price target have analysts set for GLPG?

15 brokers have issued 12-month target prices for GALAPAGOS NV/S's shares. Their forecasts range from $130.00 to $215.00. On average, they anticipate GALAPAGOS NV/S's stock price to reach $183.50 in the next twelve months. This suggests that the stock has a possible downside of 31.2%. View Analyst Price Targets for GALAPAGOS NV/S.

What is the consensus analysts' recommendation for GALAPAGOS NV/S?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GALAPAGOS NV/S.

Has GALAPAGOS NV/S been receiving favorable news coverage?

News headlines about GLPG stock have been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for GALAPAGOS NV/S.

Who are some of GALAPAGOS NV/S's key competitors?

What other stocks do shareholders of GALAPAGOS NV/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), argenx (ARGX), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Pharming Group (PHGUF), Collegium Pharmaceutical (COLL), Trade Desk (TTD), Sociedad Quimica y Minera de Chile (SQM) and Biogen (BIIB).

Who are GALAPAGOS NV/S's key executives?

GALAPAGOS NV/S's management team includes the folowing people:
  • Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
  • Mr. Bart Filius MBA, CFO & COO (Age 49)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
  • Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
  • Dr. Andre Hoekema, Chief Bus. Officer (Age 62)

When did GALAPAGOS NV/S IPO?

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are GALAPAGOS NV/S's major shareholders?

GALAPAGOS NV/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (4.82%), FMR LLC (1.10%), Bessemer Group Inc. (0.49%), Jane Street Group LLC (0.17%), Public Employees Retirement Association of Colorado (0.15%) and Bank of America Corp DE (0.12%).

Which institutional investors are selling GALAPAGOS NV/S stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Eventide Asset Management LLC, Sands Capital Management LLC, Bessemer Group Inc., Bank of America Corp DE, Bank of New York Mellon Corp, FMR LLC and Employees Retirement System of Texas.

Which institutional investors are buying GALAPAGOS NV/S stock?

GLPG stock was bought by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Acadian Asset Management LLC, Barclays PLC, Jane Street Group LLC, Russell Investments Group Ltd., Geode Capital Management LLC, Goldman Sachs Group Inc. and Atria Investments LLC.

How do I buy shares of GALAPAGOS NV/S?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GALAPAGOS NV/S's stock price today?

One share of GLPG stock can currently be purchased for approximately $266.71.

How big of a company is GALAPAGOS NV/S?

GALAPAGOS NV/S has a market capitalization of $14.62 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. View Additional Information About GALAPAGOS NV/S.

What is GALAPAGOS NV/S's official website?

The official website for GALAPAGOS NV/S is http://www.glpg.com/.

How can I contact GALAPAGOS NV/S?

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]


MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  410 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  765
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel